Cancer Cell Biology

You have full text access to this OnlineOpen article

Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis†‡

  1. Aaron Shafer§,
  2. Chunxiao Zhou§,
  3. Paola A. Gehrig,
  4. John F. Boggess,
  5. Victoria L. Bae-Jump¶,*

Article first published online: 17 AUG 2009

DOI: 10.1002/ijc.24837

Issue

International Journal of Cancer

International Journal of Cancer

Volume 126, Issue 5, pages 1144–1154, 1 March 2010

Additional Information

How to Cite

Shafer, A., Zhou, C., Gehrig, P. A., Boggess, J. F. and Bae-Jump, V. L. (2010), Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. Int. J. Cancer, 126: 1144–1154. doi: 10.1002/ijc.24837

Author Information

  1. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, Chapel Hill, North Carolina

  1. §

    Chunxiao Zhou contributed an equal amount of work as the first author

  2. Fax: 919-966-2646

*Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina, CB no. 7572, Chapel Hill, NC 27599-7572, USA

  1. †

    This work was presented at the 2008 Annual Meeting of the American Association for Cancer Research, San Diego, CA

  2. ‡

    Conflict of interest: Nothing to report

Publication History

  1. Issue published online: 27 DEC 2009
  2. Article first published online: 17 AUG 2009
  3. Accepted manuscript online: 17 AUG 2009 12:00AM EST
  4. Manuscript Accepted: 6 AUG 2009
  5. Manuscript Received: 21 MAY 2009

Funded by

  • V Foundation for Cancer Research and the Steelman Fund; Grant sponsor: UNC Clinical Translational Science Award-K12 Scholars Program) from the National Center for Research Resources. Grant Number: Award Number KL2RR025746

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (747K)

References

  • 1
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
  • 2
    Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007; 12: 9–22.
  • 3
    Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N. mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006; 94: 195–9.
  • 4
    Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2003; 2: 789–95.
  • 5
    Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998; 10: 330–6.
  • 6
    Mita M, Sankhala K, Abdel-Karim I, Mita A, Giles F. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 2008; 17: 1947–54.
  • 7
    Kopelovich L, Fay JR, Sigman CC, Crowell JA. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. Cancer Epidemiol Biomarkers Prev 2007; 16: 1330–40.
  • 8
    Shih HC, Shiozawa T, Miyamoto T, Kashima H, Feng YZ, Kurai M, Konishi I. Immunohistochemical expression of E-cadherin and β-catenin in the normal and malignant human endometrium: an inverse correlation between E-cadherin and nuclear β-catenin expression. Anticancer Res 2004; 24: 3843–50.
  • 9
    Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, Thomas G. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120: 747–59.
  • 10
    Wu C, Wangpaichitr M, Feun L, Kuo MT, Robles C, Lampidis T, Savaraj N. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005; 4: 25.
  • 11
    Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004; 10: 7031–42.
  • 12
    Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007; 13: 4261–70.
  • 13
    Faried LS, Faried A, Kanuma T, Nakazato T, Tamura T, Kuwano H, Minegishi T. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 2006; 42: 934–47.
  • 14
    Geoerger B, Kerr K, Tang CB, Fung KM, Powell B, Sutton LN, Phillips PC, Janss AJ. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001; 61: 1527–32.
  • 15
    Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10: 123–30.
  • 16
    Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006; 101: 158–67.
  • 17
    Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006; 58: 242–56.
  • 18
    Vollmer G. Endometrial cancer: experimental models useful for studies on molecular aspects of endometrial cancer and carcinogenesis. Endocr Relat Cancer 2003; 10: 23–42.
  • 19
    Lessey BA, Vendrov AE, Yuan L. Endometrial cancer cells as models to study uterine receptivity. In: KuramotoH, NishidaM, editors. Cell and molcular biology of endometrial carcinoma. Tokyo: Springer-Verlag, 2003. 267–79.
  • 20
    Bieche I, Nogues C, Paradis V, Olivi M, Bedossa P, Lidereau R, Vidaud M. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 452–9.
  • 21
    Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27–55.
  • 22
    Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. Embo J 1997; 16: 3693–704.
  • 23
    Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 2001; 15: 807–26.
  • 24
    Pause A, Methot N, Svitkin Y, Merrick WC, Sonenberg N. Dominant negative mutants of mammalian translation initiation factor eIF-4A define a critical role for eIF-4F in cap-dependent and cap-independent initiation of translation. Embo J 1994; 13: 1205–15.
  • 25
    Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003; 8: 413–50.
  • 26
    Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62: 305–13.
  • 27
    Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 2004; 91: 1420–4.
  • 28
    Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC,Jr. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 2003; 22: 484–97.
  • 29
    Sugiyama H, Papst P, Gelfand EW, Terada N. p70 S6 kinase sensitivity to rapamycin is eliminated by amino acid substitution of Thr229. J Immunol 1996; 157: 656–60.
  • 30
    Bae-Jump VL, Zhou C, Gehrig PA, Whang YE, Boggess JF. Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest. Gynecol Oncol 2006; 100: 487–94.
  • 31
    Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA 2001; 98: 9666–70.
  • 32
    Stewart SA, Weinberg RA. Telomerase and human tumorigenesis. Semin Cancer Biol 2000; 10: 399–406.
  • 33
    Yokoyama Y, Takahashi Y, Shinohara A, Lian Z, Tamaya T. Telomerase activity in the female reproductive tract and neoplasms. Gynecol Oncol 1998; 68: 145–9.
  • 34
    Zheng PS, Iwasaka T, Yamasaki F, Ouchida M, Yokoyama M, Nakao Y, Fukuda K, Matsuyama T, Sugimori H. Telomerase activity in gynecologic tumors. Gynecol Oncol 1997; 64: 171–5.
  • 35
    Mo Y, Gan Y, Song S, Johnston J, Xiao X, Wientjes MG, Au JL. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach. Cancer Res 2003; 63: 579–85.
  • 36
    Multani AS, Li C, Ozen M, Imam AS, Wallace S, Pathak S. Cell-killing by paclitaxel in a metastatic murine melanoma cell line is mediated by extensive telomere erosion with no decrease in telomerase activity. Oncol Rep 1999; 6: 39–44.
  • 37
    Calastretti A, Bevilacqua A, Ceriani C, Vigano S, Zancai P, Capaccioli S, Nicolin A. Damaged microtubules can inactivate BCL-2 by means of the mTOR kinase. Oncogene 2001; 20: 6172–80.
  • 38
    Bae-Jump V, Zhou C, Boggess JB, Whang YE, Gehrig PA. Synergistic effect of cisplatin and rapamycin in endometrial cancer cells. Gynecologic Oncology 2007; 104( suppl. 1): S54.
  • 39
    Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 2007; 14: 839–45.
  • 40
    Blagosklonny MV, Robey R, Sackett DL, Du L, Traganos F, Darzynkiewicz Z, Fojo T, Bates SE. Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 2002; 1: 937–41.
  • 41
    Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S, Nicolin A. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene 2004; 23: 5781–91.
  • 42
    Asnaghi L, Bruno P, Priulla M, Nicolin A. mTOR: a protein kinase switching between life and death. Pharmacol Res 2004; 50: 545–9.
  • 43
    Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008; 11: 63–76.
  • 44
    VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther 2004; 3: 1605–13.
  • 45
    Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 2009; 115: 3887–96.
  • 46
    Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gynecol Oncol 2004; 94: 785–95.
View Full Article (HTML) Get PDF (747K)